10-Q · May 7, 2026
Lantheus reported a solid Q1 2026 with revenue of $377.3 million, exceeding estimates and achieving an EPS of $1.80, reflecting a 62.3% increase in net income year-over-year. However, gross profit declined slightly,…
LNTH earnings analysis
10-Q · Filed November 5, 2026 · Our reading of the company's report
The latest report
Lantheus reported third-quarter revenue of $389.9 million and diluted EPS of $0.33, with revenue modestly above both the prior quarter’s $388 million and the year-ago quarter’s $384 million. GAAP earnings remain…
Read full summary
Lantheus reported third-quarter revenue of $389.9 million and diluted EPS of $0.33, with revenue modestly above both the prior quarter’s $388 million and the year-ago quarter’s $384 million. GAAP earnings remain pressured by $31.0 million of intangible-asset impairments. The pending Curium merger, including the FTC’s October 21 Second Request and potential $228.0 million termination fee, remains the principal near-term uncertainty, while full-year 2026 guidance has been withdrawn.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $0.33
What stood out
-
Revenue modestly higher sequentially and year over year
Third-quarter revenue was $389.9 million, up from $388 million in the prior quarter and $384 million in the year-ago quarter based on the provided quarterly history.
-
Material strategic investment portfolio
The company reported $96.3 million of equity investments in Perspective Therapeutics, Radiopharm Theranostics and Illuminated Holdings, exposing the balance sheet to equity-price volatility.
-
Regulatory progress in imaging portfolio
Lantheus received FDA approval for TAUKLARIFY on August 14, 2026 and CMS granted PYLARIFY TruVu TPT Status effective October 1, 2026, supporting its neurology and prostate-imaging portfolios.
-
BRAVNETSA received final FDA approval
The company received final FDA approval for BRAVNETSA on September 22, 2026, although launch timing remains subject to Hatch-Waxman litigation and commercial readiness.
-
Repurchase capacity preserved
The company retained $200.0 million of remaining authorization under its share-repurchase program through December 2027 and made no repurchases under that program during the three months ended September 30, 2026.
What to watch
-
Curium merger faces regulatory and closing risk
The FTC issued a Second Request on October 21, 2026, extending the HSR waiting period until 30 days after substantial compliance unless terminated sooner. The merger consideration includes $102.50 per share plus a CVR of up to $12.00, and the company may owe a $228.0 million termination fee in specified circumstances.
-
Intangible impairments pressure GAAP earnings
Third-quarter impairment charges totaled $31.0 million, including $21.0 million for LNTH-2620 and $10.0 million for LNTH-2515. Further clinical, regulatory or commercial setbacks could result in additional impairment charges.
-
TruVu launch and reimbursement uncertainty
PYLARIFY TruVu is expected to become commercially available beginning in the fourth quarter of 2026, but TPT Status is temporary and the company cannot assure timely technology transfer, PMF approvals or customer adoption.
Management's outlook
The company withdrew previously issued full-year 2026 financial guidance because of the pending Curium merger; no replacement quantitative revenue or EPS guidance was provided.
Earlier filings 4
10-K · February 26, 2026
Lantheus’ 10-K emphasizes a strategy focused on PET radiodiagnostics and microbubbles, highlighted by multiple 2025 acquisitions (Life Molecular and Evergreen) and the post-period divestiture of its SPECT business to…
10-Q · May 7, 2025
Lantheus reported revenue of $372,764,000 for the three months ended March 31, 2025, up $2,789,000 versus $369,975,000 in Q1 2024, while diluted EPS fell to $1.02 from $1.87 a year ago. Gross margin was 63.8% and…
10-K · February 26, 2025
Lantheus describes a deliberate strategy to evolve into a fully integrated radiopharmaceutical company, expanding through targeted M&A and in‑licensing while commercializing core products (PYLARIFY, DEFINITY) and…
Smart money in LNTH
Totals from the last full session. Insider and politician figures cover 90 days.
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.
See every LNTH trade live.
The free pages stop at the last full session. Trader shows every trade as it prints.
Start tracking No card needed.